ArticleScience (New York, N.Y.)2021
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
112citing papers in PubMed, 2 pooled it
14.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 2 syntheses or guidelines pooled it, 196 citations in OpenAlex.
- Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.Journal for immunotherapy of cancer · 2025Guideline
- Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.Frontiers in immunology · 2023Pooled it
- Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.Molecular cancer · 2022Trial
- 3D multi-omics tumour atlases: from technology to biology and clinical translation.Nature reviews. Cancer · 2026Review
- Multimodal Artificial Intelligence in Lung Cancer: From Data Integration to Precision Oncology.Cancers · 2026Review
- Spatial omics illuminates tumor heterogeneity.Cell reports methods · 2026Review
- CellTune: an integrative software for accurate cell classification in spatial proteomics.Nature methods · 2026Article
- Review
- Multimodal spatial omics: From data acquisition to computational integration.Patterns (New York, N.Y.) · 2026Review
- Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.Nature medicine · 2026Article
- Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery.Journal for immunotherapy of cancer · 2026Article
- Neoadjuvant PD-1 inhibitor combined with FLOT versus SOX for locally advanced gastric cancer: a retrospective cohort study.Frontiers in immunology · 2026Article
- Spatial immune ecology of immunotherapy resistance in gastric and gastroesophageal junction adenocarcinoma.Frontiers in oncology · 2026Review
- AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery.Journal for immunotherapy of cancer · 2025Article
- Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).Journal for immunotherapy of cancer · 2025Article
- Development of a Multispectral Image Database in Visible-Near-Infrared for Demosaicking and Machine Learning Applications.Journal of imaging · 2025Article
- Novel Predictive Spatial Biomarker in Non-Small Cell Lung Carcinoma: The Diversity of Niches Unlocking Treatment Sensitivity (DONUTS).bioRxiv : the preprint server for biology · 2025Article
- Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8JCO precision oncology · 2025Article
- Insights into the Mechanisms of Immune-Checkpoint Inhibitors Gained from Spatiotemporal Dynamics of the Tumor Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Recent Advances in Molecular Research and Treatment for Melanoma in Asian Populations.International journal of molecular sciences · 2025Review
52 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
37 authors at 2 institutions in 1 country.
Sneha Berry *The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-4887-8969
Nicolas A Giraldo *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-7452-1103
Benjamin F Green *The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
Tricia R CottrellDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-2952-1830
Julie E SteinDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-8040-5205
Elizabeth L EngleThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
Haiying XuThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
Aleksandra OgurtsovaThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
Charles RobertsBloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Daphne WangDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-7202-8075
Peter NguyenDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Qingfeng ZhuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-7871-3359
Sigfredo Soto-DiazBloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.
Jose LoyolaBloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-0746-2174
Inbal B SanderDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Pok Fai WongDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
Shlomit JesselDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0001-8489-0351
Joshua DoyleDepartment of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.
Danielle SignerDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-5825-7525
Richard WiltonDepartment of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0003-1263-5532
Jeffrey S RoskesDepartment of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0001-8761-0490
Margaret EminizerDepartment of Astronomy and Physics, Johns Hopkins University, Baltimore, MD 21218, USA.ORCID 0000-0003-4591-2225
Seyoun ParkThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-6987-9362
Joel C SunshineDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0001-9987-6712
Elizabeth M JaffeeThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0003-3841-6549
Alexander BarasDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-2397-3342
Angelo M De MarzoDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-4847-5307
Suzanne L TopalianBloomberg~Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-0821-8587
Harriet KlugerDivision of Medical Oncology, Department of Medicine, Yale University School of Medicine, New Haven, CT 06510, USA.
Leslie CopeThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-4098-3289
Evan J LipsonThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0003-2976-0911
Ludmila DanilovaThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0003-2813-3094
Robert A AndersThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.
David L RimmDepartment of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0001-5820-4397
Drew M PardollThe Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0001-6215-1013
Alexander S Szalay *The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA.ORCID 0000-0002-4108-3282
Janis M Taube *The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, MD 21287, USA. jtaube1@jhmi.edu.ORCID 0000-0002-8273-4395
Johns Hopkins University · USYale University · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6MYale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI MARCUS W BOSENBERG, Harriet M. Kluger · 2006 to 2026
$43.9MTransforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A. · 2021 to 2025
$12.7MPD-1/PD-L1 modulation in cancer therapyR01CA142779 · NCI · JOHNS HOPKINS UNIVERSITY · PI PARDOLL, DREW M., TAUBE, JANIS M · 2010 to 2025
$8.2MMultidiciplinary Integrative Genomic Approach to Distinguish Lethal from Indolent Prostate Cancer in Men of Europena and African AncestryU01CA196390 · NCI · JOHNS HOPKINS UNIVERSITY · PI DE MARZO, ANGELO MICHAEL, PIENTA, KENNETH J. · 2015 to 2020
$5.8MTargeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical TrialR01CA197296 · NCI · JOHNS HOPKINS UNIVERSITY · PI William Reece Burns, Eric Christenson · 2015 to 2026
$5.7MOpportunities for Pathology Trainees in Cancer ResearchT32CA193145 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A., EBERHART, CHARLES G · 2015 to 2025
$2.6MComprehensive Analysis and Multi-Omics Data Integration for Cancer-Related StudiesR50CA243627 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ludmila Danilova · 2019 to 2026
$975kNCATS NIH HHS UL1 TR001863NCI NIH HHS P01 CA247886NCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA121974NCI NIH HHS R01 CA142779NCI NIH HHS R01 CA197296NCI NIH HHS R50 CA243627NCI NIH HHS T32 CA193145NCI NIH HHS U01 CA196390
Abstract
Next-generation tissue-based biomarkers for immunotherapy will likely include the simultaneous analysis of multiple cell types and their spatial interactions, as well as distinct expression patterns of immunoregulatory molecules. Here, we introduce a comprehensive platform for multispectral imaging and mapping of multiple parameters in tumor tissue sections with high-fidelity single-cell resolution. Image analysis and data handling components were drawn from the field of astronomy. Using this "AstroPath" whole-slide platform and only six markers, we identified key features in pretreatment melanoma specimens that predicted response to anti-programmed cell death-1 (PD-1)-based therapy, including CD163
Indexed as
Fluorescent Antibody TechniqueAdultAgedAged, 80 and overAntigens, CDAntigens, Differentiation, MyelomonocyticAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD163 AntigenCD8 AntigensFemaleForkhead Transcription FactorsHumansImmune Checkpoint ProteinsMacrophagesAntigens, CDAntigens, Differentiation, MyelomonocyticAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCD163 AntigenCD274 protein, humanCD8 AntigensForkhead Transcription FactorsFOXP3 protein, humanImmune Checkpoint ProteinsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Cell SurfaceSOX10 protein, humanSOXE Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.